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Chun-Song Yang, Ling-Li Zhang*, Li-Nan Zeng, Yi Liang, Lu Han and Yun-Zhu LinAbstract
Background: Quality assessment of pediatric randomized controlled trials (RCTs) in China is limited. The aim of this
study was to evaluate the quantitative trends and quality indicators of RCTs published in mainland China over a
recent 10-year period.
Methods: We individually searched all 17 available pediatric journals published in China from January 1, 2002 to
December 30, 2011 to identify RCTs of drug treatment in participants under the age of 18 years. The quality was
evaluated according to the Cochrane quality assessment protocol.
Results: Of 1287 journal issues containing 44398 articles, a total of 2.4% (1077/44398) articles were included in the
analysis. The proportion of RCTs increased from 0.28% in 2002 to 0.32% in 2011. Individual sample sizes ranged
from 10 to 905 participants (median 81 participants); 2.3% of the RCTs were multiple center trials; 63.9% evaluated
Western medicine, 32.5% evaluated traditional Chinese medicine; 15% used an adequate method of random
sequence generation; and 10.4% used a quasi-random method for randomization. Only 1% of the RCTs reported
adequate allocation concealment and 0.6% reported the method of blinding. The follow-up period was from 7 days
to 96 months, with a median of 7.5 months. There was incomplete outcome data reported in 8.3%, of which 4.5%
(4/89) used intention-to-treat analysis. Only 0.4% of the included trials used adequate random sequence allocation,
concealment and blinding. The articles published from 2007 to 2011 revealed an improvement in the
randomization method compared with articles published from 2002 to 2006 (from 2.7% to 23.6%, p = 0.000).
Conclusions: In mainland China, the quantity of RCTs did not increase in the pediatric population, and the general
quality was relatively poor. Quality improvements were suboptimal in the later 5 years.
Keywords: Children, Drugs, Randomized controlled trials, Quality assessmentBackground
Randomized controlled trials (RCTs) provide reliable
evidence to guide clinical practice. However, difficulties
in obtaining a guardian’s consent, obtaining research
funding, and ethical concerns [1-3] often limit the con-
duction of RCTs in children. More attention should be
paid to the quality of research in clinical trials evaluating
drugs in children, which would lead to improvements in
pediatric clinical practices. Al-Namankany et al. [4]
showed that the proportion of studies in pediatric den-
tistry journals using random sequence generation was* Correspondence: zhlingli@sina.com
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© 2013 Yang et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the or28% and allocation concealment was 6%. Crocetti et al.
[5] found that a large proportion of pediatric RCT re-
ports in eight prominent journals between July 1, 2007
and June 30, 2008 had a high risk of bias. Hamm et al.
[6] also found that more than half of a random sample
of 300 pediatric RCTs published in 2007 had a high risk
of bias. Wu et al. [7] found that only 6.6% of RCTs pub-
lished in Chinese journals used adequate methods of
random sequence generation. These previous studies
provided insightful information on the quality of pediatric
RCTs. However, they did not examine whether there was
an improvement in quality nor give details of quantitative
trends over a period.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Details of assessment of the risk of bias
Allocation sequence
generation
Allocation concealment Blinding Incomplete outcome data Selective reporting Other sources of
bias
Low risk The researchers describe a








to be free of other
sources of bias, etc.
1. A random number
table;




1. No blinding or incomplete
blinding, but the review authors
judge that the outcome is not
likely to be influenced by lack of
blinding;
1. No missing outcome data; 1. All outcomes described are
included and reported in the
analysis;





2. Blinding of participants and key
study personnel ensured, and
unlikely that the blinding could
have been broken, etc.
2. Missing outcome data balanced
in number across intervention
groups, with similar reasons for
missing data across groups;
2. For registered trials, all
outcomes reported are
included in the analysis;
3. Coin tossing; 3. Sequentially numbered,
opaque, sealed envelopes,
etc.
3. Missing data have been imputed
using appropriate methods, etc.
3. All outcomes expected to
have been collected for the
condition are reported, etc.
4. Throwing dice;
5. Drawing of lots, etc.





by odd or even date of
birth;
1. Use of an open random
allocation schedule;
1. No blinding or incomplete
blinding for an outcome that was
likely to be affected by blinding.
1. Reason for missing outcome data
likely to be related to true outcome,
with either imbalance in numbers or
reasons for missing data across
intervention groups;
1. Not all of the study’s pre-
specified
primary outcomes have been
reported;
1. Had a potential
source of bias
related to the specific
study design used;
2. Rule based on date
(or day) of admission;
2. Date of birth; 2. Blinding procedures could have
been broken, etc.
2. “As-treated” analysis done with
substantial difference in the
intervention received from that
assigned at randomization, etc.
2. One or more primary outcomes
is reported using measurements,
analysis methods or subsets of the
data (e.g., subscales) that were not
pre-specified;
2. Has been claimed
to have been
fraudulent, etc.
3. Based on hospital or
clinic record number, etc.
3. Case record number,
etc.
3. The study report fails to include
results for a key outcome that
would be expected to have been





Insufficient information to permit
judgment;
1. Insufficient reporting of attrition/
exclusions to permit judgment;




The study did not address this
outcome, etc.


















Excluded by screening the 
title and




Total RCTs identified (n=1077) 




Figure 1 Flow diagram showing selection of the trials.
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http://www.biomedcentral.com/1471-2431/13/113In this study, we analyzed RCTs evaluating drug treat-
ment in 17 Chinese pediatric journals in a recent 10-year
period to elucidate information about the quantitative
trends and quality of these studies in mainland China.
Methods
We individually searched currently available pediatric
journals published from January 1, 2002 to December
30, 2011 in mainland China. There are a total of 17
pediatric medical journals, namely Chinese Pediatrics of
Integrated Traditional and Western Medicine, Chinese
Journal of Neonatology, Journal of China Pediatric Blood
and Cancer, Journal of Clinical Pediatric Surgery, Chin-
ese Journal of Evidence-Based Pediatrics, Journal of
Clinical Pediatrics, Journal of Applied Clinical Pediatrics,
Chinese Journal of Contemporary Pediatrics, Chinese
Journal of Practical Pediatrics, Chinese Journal ofFigure 2 Increase in the quantity of pediatric RCTs published in mainPediatrics, Chinese Journal of Pediatric Surgery, Chinese
Journal of Obstetrics & Gynecology and Pediatrics, Inter-
national Journal of Pediatrics, Chinese Pediatric Emer-
gency Medicine, Journal of Pediatric Pharmacy, Chinese
Journal of Perinatal Medicine, and Journal of Pediatrics of
Traditional Chinese Medicine.
Inclusion and exclusion criteria
We included RCTs with participants under the age of
18 years and which used a pharmaceutical intervention.
We excluded reviews, self-control studies and trials with
more than two intervention groups.
Selection of studies and data extraction
One reviewer screened the titles and abstracts of every
article that was published in the included journals. The
full articles were obtained and further evaluated by the
selection criteria outlined above. For the selected RCTs,
two reviewers independently performed data extraction.
The extracted data included: (1) the year of publication;
(2) the general characteristics: the research institutions,
multicenter or single center, sample size, comparability
of baseline characteristics, and the funding resources,
etc.; and (3) quality assessment (see Quality assessment
section below). Discrepancies were resolved through
discussion.
Quality assessment
Evaluation of the quality of the research methods was
based on the Cochrane quality assessment list [8]. Two
reviewers independently used the criteria for the evalu-
ation process. The criteria were as follows: (1) random
sequence generation; (2) allocation concealment; (3)
blinding; (4) incomplete outcome data; (5) selective
reporting; and (6) other sources of bias. Discrepancies
were resolved through discussion. The details of assess-
ment of bias are listed in Table 1.
Data management and analysis
Continuous variables were analyzed using mean values
and standard deviations or median and interquartile
range, while categorical variables were analyzed usingland China from 2002 to 2011.





Teaching hospitals 254 (23.6%)
Non-teaching hospitals 818 (75.9%)












Pharmaceutical company sponsored Unclear
Intervention
Western medicine 688 (63.9%)
Traditional Chinese medicine 350 (32.5%)






Placebo control 12 (1.1%)
Positive drug 461 (42.8%)
Open control 604 (56.1%)
Sample size calculation
Stated 7 (0.6%)




Report of adverse events
Stated adverse events 279 (25.9%)
Stated no adverse events 251 (23.3%)
Not stated 547 (50.8%)
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test were used to test differences in continuous variables
as appropriate, and the χ2 test was used for proportions.
Data management and analysis were performed with the
SPSS v. 16.0 (SPSS Inc., Chicago, IL, USA).
Results
General characteristics
After screening 44398 articles published in the 17 Chinese
pediatric medical journals, a total of 1077 RCTs were in-
cluded in the analysis (Figure 1). Over the 10-year period,
the proportion of RCTs in mainland China increased from
0.28% in 2002 to 0.32% by 2011 (Figure 2). There was no
significant increase in the number of RCTs conducted an-
nually. Only 4.09% of the trials reported financial funding;
however, we could not confirm that how many trials were
sponsored by pharmaceutical companies because the in-
formation was not given. Individual study sample sizes
ranged from 10 to 905 (median 81 participants). Only
0.6% (7/1077) of RCTs reported that calculation of sample
size had been performed, and 2.3% (25/1077) of RCTs in-
cluded multiple centers, with the number of participating
centers ranging between two and ten. Nearly one-quarter
(254/1077) of RCTs were conducted in teaching hospitals,
63.9% (688/1077) evaluated Western medicine, 32.5%
(350/1077) evaluated traditional Chinese medicine, and
3.6% (39/1077) evaluated a combination of both trad-
itional Chinese and Western medicine (Table 2). The top
five categories of disease included respiratory (41.6%),
neonatal (19.9%), digestive (14.7%), infection (5.7%), and
neuromuscular (4.4%) diseases (Figure 3).
Quality assessment
Randomization methods
The results are presented in Table 3: 15% (161/1077) of
RCTs used an adequate method of random sequence
generation; 74.6% (803/1077) denoted “random alloca-
tion” in the study without a specific description; and
10.4% (113/1077) regarded quasi-randomization as cor-
rect randomization, and the most common methods for
allocating participants used were the visiting sequence of
inpatient/outpatient, the card number of the inpatient/
outpatient number or patient birth date.
Allocation concealment
Only 1% (10/1077) of RCTs reported reasonable alloca-
tion concealment, including central allocation and sealed
opaque envelopes; 99% (1067/1077) of trials did not in-
dicate the allocation concealment method.
Blinding
Only 0.6% (6/1077) of RCTs reported the blinding
method (0.3% single-blind for participants, 0.2% double-
blind for participants and investigators, 0.1% triple-blindfor participants, investigators and assessors); 1.6% of
RCTs (17/1077) reported blinding without full disclosure
of the method; and 97.8% (1054/1077) did not mention
the use of blinding in the trials.
Figure 3 Distribution of disease states among 1077 RCTs in pediatric journals published in mainland China from 2002 to 2011.
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Only 1.1% (22/1077) of RCTs were placebo-controlled,
56.1% (604/1077) were open control and 42.8% (461/1077)
were positive drug control. “Open control” was defined as
having two groups with the same standard treatment with
intervention in the treatment group (i.e., standard treat-
ment + test drug versus standard treatment). “Positive drug
control” was defined as the control group having an active
control (i.e., test drug versus control drug, or standard
treatment + test drug versus standard treatment + control
drug). A positive result was reported in 95.5% (1028/1077)
of trials; 4% (43/1077) of trials used laboratory data as indi-
cators of efficacy and 58% (625/1077) used endpoint out-
comes, while 38% (409/1077) used both laboratory data
and endpoint outcomes. The follow-up period ranged from
7 days to 96 months, with a median of 7.5 months. Incom-
plete outcome data was reported in 8.3% (89/1077) of tri-
als, of which 4.5% (4/89) used intention-to-treat analysis;
49.2% (530/1077) of trials reported adverse events, of
which 52.6% (279/530) reported specific adverse events,
and 47.4% (251/530) reported no adverse events; 1.7%
(18/1077) of trials showed obvious selective reporting
(outcomes described in the methodology were not
reported in the results); in 98.3% (1059/1077) the
possibility of selective reporting could not be evalu-
ated because none of the included studies had been
registered, and we were unable to compare the re-
search with the protocol. In general, 0.4% (4/1077)
reported all random sequence, allocation conceal-
ment, and blinding methods.
Bias from other sources
In 0.2% (2/1077) of RCTs, the reported baseline data in
the treatment and control groups were not comparable.
Subgroup analysis
We conducted a subgroup analysis to determine which
factors influenced the quality of the included studies.The quality of RCTs conducted in multiple centers was
superior to those of single centers regarding random se-
quence generation, allocation concealment, and blinding.
The quality of allocation concealment and blinding but
not random sequence generation, was also better in
teaching hospitals compared with non-teaching hospi-
tals. In contrast, incomplete outcome data was more
likely in RCTs from multiple centers and in teaching
hospitals. Trials with financial funding performed better
for allocation concealment than trials without funding.
However, we could not explore the influence of pharma-
ceutical industry funding on quality because sponsorship
information was not reported. The RCTs published from
the 2007 to 2011 revealed an improvement in the
randomization method compared with 2002–2006 (from
2.7% to 23.6%). There was also a trend for improvement
in allocation concealment (p = 0.053) (Table 4).
Discussion
This study showed that the number and the quality of
Chinese pediatric RCTs improved slightly during the
past decade. It had been reported that the number of
adult RCTs was 2.7 times that of pediatric RCTs in six
medical journals [9]. The number of pediatric RCTs in-
creased from 0.4 to 16.9 per year, while adult RCTs in-
creased from 4.71 to 90.5 per year [10-13]. Owing to a
lack of pediatric RCTs, use of drugs in pediatric settings
are often forced to extrapolate from the results of clin-
ical trials in adults, which is inappropriate [10,14]: on
the one hand, there are many differences in physiological
function, pharmacokinetics, and pharmacodynamics be-
tween children and adults, thus the administration of
unevaluated pharmaceutics in children by extrapolation
could have no effect or be harmful [15]; on the other
hand, this would result in off-label drug use, which is
relevant to the occurrence of adverse events [16]. Re-
ports indicate that the rate of off-label pharmaceutical
use in pediatric settings ranges from 11% to 46%




Method of random sequence generation
Low risk 161 (14.9%)
Random number table 121 (11.2%)
Drawing of lots 28 (2.6%)
Computer 9 (0.8%)
Lottery 1 (0.1%)
Coin toss 1 (0.1%)
Dice 1 (0.1%)
High risk
Visiting sequence of inpatient/outpatient, the card
number of inpatient/outpatient number and birth date.
113 (10.5%)
Unclear 803 (74.6%)
Method of allocation concealment
Low risk 10 (1%)
Central allocation 7 (0.7%)




Low risk 6 (0.6%)
Single blind (participants) 3 (0.3%)
Double blind (participants and investigators) 2 (0.2%)















High risk 2 (0.2%)
Unclear 1075 (99.8%)
– means no data available.
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off-label drug use in China is 78.96% in hospitalized
children [24]. In accordance with the prevalence of off-
label drug use in pediatric settings, the risk of adverseeffects has been reported to be three times as high as
in adults [25].
There are five major reasons for the limited clinical
trials of drugs in children: (1) the spectrum of diseases is
narrow and the incidence of disease in children is low
compared with adults [11]; (2) difficulties in obtaining
consent from guardians limit the number of participants
available for clinical trials [3,14,26]; (3) the unwillingness
of researchers to conduct research as a result of the ex-
tensive pressures exerted by ensuring participants’ rights
in trials and minimizing risk in clinical trials [27]; (4) the
limited financial support from pharmaceutical compan-
ies because of the high cost of research and the low
beneficial return; and (5) the lack of public policies
supporting a re-evaluation of procedures for off-label
drug use [11,15].
There was a median of 81 participants in the published
pediatric RCTs in China, which is lower than in inter-
national studies (median of 272 participants). In addition,
the proportion reporting sample size calculation in
Chinese pediatric RCTs was also lower than in inter-
national pediatric RCTs (4–65%) [11,28] and adult
RCTs (23–64%) [28-30]. The proportion of multiple
center pediatric RCTs in China (2.3%) was also lower
than the adult RCTs (28–67%) worldwide [11,28].
Inadequate or unclear research methods of allocation
concealment and random allocation signify low quality
clinical trials and may exaggerate efficacy by as much as
30–41% [31-33]. Compared with the analysis of studies
in pediatric dentistry conducted by Al-Namankany et al.
[4], the proportion of studies with adequate randomization
and blinding was low, while use of intention-to-treat ana-
lysis was similar to our study. Compared with adult RCTs,
the proportion with adequate randomization in our study
was similar to the international level (14–39%), and alloca-
tion concealment, blinding, and intention-to-treat analysis
were at a lower level than the international standard (allo-
cation concealment 13–40%, blinding 19–45%, intention-
to-treat analysis 12–43%) [28-30,34].
The main problems in the pediatric RCTs in China
were as follows: (1) studies were often labeled “ran-
dom” without giving details on random sequence gen-
eration, and some researchers erroneously regarded
the quasi-random process as the correct method for
randomization; (2) outcome measurements using
blinding methodology were ignored, and explanations
of the use of blinding methodologies were vague; (3)
most RCTs used active drugs whose efficacy was un-
clear as control, and few used a placebo control; (4)
RCTs focused on the evaluation of short-term efficacy,
and had no discussion of long-term efficacy; (5) ad-
verse effects were often ignored or not reported; and
(6) there was lack of clinical trial registration making it
difficult to monitor the quality of the conduction and
























5 (20%) 5 (0.48%) 0.000 9 (3.54%) 1 (0.12%) 0.000 3 (6.82%) 7 (0.68%) 0.006 1 (0.22%) 9 (1.43%) 0.053
(n = 10)




12 (48%) 976 (92.78%) 0.000 214 (84.25%) 769 (94.01%) 0.000 29 (65.9%) 959 (92.84%) 0.000 416 (93.27%) 572 (90.65%) 0.123
(n = 988)
Selective reporting 0 (0%) 18 (1.71%) 1.000 3 (1.18%) 15 (1.83%) 0.588 0 (0%) 18 (1.74%) 1.000 6 (1.35%) 12 (1.9%) 0.483
(n = 18)
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http://www.biomedcentral.com/1471-2431/13/113reporting of trials. Further studies should overcome
these drawbacks.
The quality of the published RCTs in China did show
an increase in the reported random sequence generation
methods in studies published from 2007 to 2011 com-
pared with 2002 to 2006. The proportion with adequate
use of randomized sequence generation methods increased
from 2.7% to 23.6%. The following factors may have con-
tributed to the increased use of randomized sequence
generation: (1) a rapid development of evidence-based
medicine in China; (2) greater awareness by clinicians
of the importance of quality in clinical research for
clinical decision-making; and (3) improved quality of re-
search, with Consolidated Standards Of Reporting Trials
(CONSORT) publications available to researchers to
scrutinize standard RCTs. Compared with the quality of
international clinical trials, only 25% of the pediatric trials
published in China achieved adequate random sequence
generation, which still leaves major opportunities for im-
provement. The quality of multiple center RCTs in China
was better than in single center studies, which was con-
sistent with international reports [35].
There were several limitations in our study: (1) assess-
ment of the quality of RCTs was based on the descrip-
tion in the articles without verification from the original
authors. However, a verification process suggested there
would be no significant improvement in the assessment
[7]; (2) we only included RCTs of drug interventions and
excluded non-drug therapy (such as physical therapy or
surgery); in addition, we also excluded more than two
intervention groups, and as it is more difficult to control
quality in these studies, our study may have overestimated
the quality of pediatric RCTs in China; and (3) we only in-
cluded trials published in pediatric professional journals,
and other general medical journals could contain pediatric
RCTs.
Conclusions
In mainland China, the quantity of RCTs did not in-
crease over 10 years in the pediatric population, and the
general quality remained relatively poor. There was an
improvement in quality in the latest 5 years, but this was
suboptimal.
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